MLchartDataset catalogue

anti-PD-1/anti-TGFbRII bispecific antibody INCA33890

Term · Oncology and biomedicine · MLC-T-ONC-010978

A bispecific antibody directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279) and human transforming growth factor beta (TGF-beta) receptor II (TGFbRII), with potential immune checkpoint modulating and antineoplastic activities. Upon administration, anti-PD-1/anti-TGFbRII bispecific antibody INCA33890 targets and binds to both PD-1 and TGFbRII and prevents the activation of PD-1 and TGF-beta-mediated signaling pathways in the tumor microenvironment (TME). The binding of INCA33890 to PD-1 prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1; CD274) and/or 2 (PD-L2; CD273). This abrogates T-cell inhibition, activates antigen-specific T lymphocytes and enhances cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which may lead to a reduction in tumor growth. The binding of INCA33890 to TGFbRII prevents the binding of TGF-beta to TGFbRII, thereby preventing the activation of the TGF-beta-mediated signaling pathway. This abrogates TGF-beta-mediated immunosuppression in the TME, increases natural killer (NK) cell and CTL activities, and inhibits tumor cell proliferation in susceptible tumor cells. PD-1, an inhibitory receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated T lymphocytes; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands and plays an important role in tumor evasion from host immunity. TGF-beta, a pro-inflammatory mediator, is upregulated in certain types of cancers and is involved in cancer cell proliferation, tumor progression, migration and invasion, and the suppression of the immune response.

Table 1. Record
IdentifierMLC-T-ONC-010978
FieldOncology and biomedicine
Synonymsanti-PD-1/TGFbRII bispecific antibody INCA33890; PD-1 x TGFbR2 bispecific antibody INCA33890; PD-1 x TGFbRII bispecific antibody INCA33890
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010978",
  "term": "anti-PD-1/anti-TGFbRII bispecific antibody INCA33890",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279) and human transforming growth factor beta (TGF-beta) receptor II (TGFbRII), with potential immune checkpoint modulating and antineoplastic activities. Upon administration, anti-PD-1/anti-TGFbRII bispecific antibody INCA33890 targets and binds to both PD-1 and TGFbRII and prevents the activation of PD-1 and TGF-beta-mediated signaling pathways in the tumor microenvironment (TME). The binding of INCA33890 to PD-1 prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1; CD274) and/or 2 (PD-L2; CD273). This abrogates T-cell inhibition, activates antigen-specific T lymphocytes and enhances cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which may lead to a reduction in tumor growth. The binding of INCA33890 to TGFbRII prevents the binding of TGF-beta to TGFbRII, thereby preventing the activation of the TGF-beta-mediated signaling pathway. This abrogates TGF-beta-mediated immunosuppression in the TME, increases natural killer (NK) cell and CTL activities, and inhibits tumor cell proliferation in susceptible tumor cells. PD-1, an inhibitory receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated T lymphocytes; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands and plays an important role in tumor evasion from host immunity. TGF-beta, a pro-inflammatory mediator, is upregulated in certain types of cancers and is involved in cancer cell proliferation, tumor progression, migration and invasion, and the suppression of the immune response.",
  "synonyms": [
    "anti-PD-1/TGFbRII bispecific antibody INCA33890",
    "PD-1 x TGFbR2 bispecific antibody INCA33890",
    "PD-1 x TGFbRII bispecific antibody INCA33890"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-pd-1-anti-tgfbrii-bispecific-antibody-inca33890/"
}

Record 2,108 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.